ERBB2 and neoplasm: In our previous work with metastatic HER2+ breast cancer12, a high number of cytotoxic CD8+ T-cells in the center of the tumour, but not in the invasive margin, was significantly associated with the improved survival and patient’s ability to remain disease progression-free without trastuzumab after initially responding to the therapy.